Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antiĀ–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Eris Lifesciences Limited's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.885000
forwardPE 29.509203
debtToEquity 75.737000
earningsGrowth 0.322000
revenueGrowth 0.284000
grossMargins 0.752020
operatingMargins 0.249270
trailingEps 25.820000
forwardEps 41.650000

Eris Lifesciences Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
ERIS's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with ERIS expected to increase its market presence and profitability.
ERIS's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
Eris Lifesciences Limited's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that Eris Lifesciences Limited is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for ERIS
Price projections for ERIS

Eris Lifesciences Limited's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about Eris Lifesciences Limited's ability to generate strong results going forward.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


The recent buy bias for ERIS from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see ERIS as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.